Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 11/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498276 | 0.89 | KDM4E (0.42) | PDE2APDE10ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL121472 | 0.81 | HTR3E (0.45) | IKBKBPDE2APDE10ACYP11B2CYP11B1 | |
| SCHEMBL8102963 | 0.81 | CUL4A (0.51) | IKBKBPDE2APDE10ACYP1A2CYP2C9 | |
| SCHEMBL17895304 | 0.80 | IKBKB (0.68) | IKBKBPDE2APDE10APDE7A | |
| SCHEMBL24832295 | 0.78 | IKBKB (0.45) | IKBKBPDE2APDE10ACYP1A2CYP2C19 | |
| SCHEMBL13077027 | 0.78 | IKBKB (0.66) | IKBKB | |
| SCHEMBL25824093 | 0.78 | IKBKB (0.45) | IKBKB | |
| SCHEMBL30973203 | 0.78 | IKBKB (0.45) | IKBKB | |
| SCHEMBL12329839 | 0.78 | HTR3E (0.50) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3495003 | 0.76 | RPS6KA5 (0.33) | IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | IKBKB 1832/4885PDE2A 1534/4885PDE10A 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.